NCT03769129 is a NA clinical trial of Pembrolizumab in Non Small Cell Lung Cancer, sponsored by Second Affiliated Hospital of Guangzhou Medical University.

Who is sponsoring NCT03769129?

NCT03769129 is sponsored by Second Affiliated Hospital of Guangzhou Medical University.

What drugs are being tested in NCT03769129?

Interventions in NCT03769129: Pembrolizumab, microwave ablation.

What condition does NCT03769129 study?

NCT03769129 studies Non Small Cell Lung Cancer.

Is NCT03769129 still recruiting?

NCT03769129 is currently recruiting now. Last updated 25 June 2024.

Last reviewed 2024-06-25 · How we verify

NCT03769129

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC

Recruiting now NA Last updated 25 June 2024

What this trial tests

NA trial testing Pembrolizumab in Non Small Cell Lung Cancer in 100 participants. Currently enrolling.

Timeline

1 November 2018

Primary endpoint
1 November 2026

1 November 2029

Quick facts

Lead sponsor	Second Affiliated Hospital of Guangzhou Medical University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 November 2018
Primary completion	1 November 2026
Estimated completion	1 November 2029
Sites	1 location across China

Drugs / interventions tested

Pembrolizumab (pembrolizumab) — full drug profile →
microwave ablation

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Who can join

18 and older, any sex, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, randomized, single clinical study designed to evaluate its safety and efficacy by using Microwave Ablation combine with Pembrolizumab in patients with Stage ⅢB-Ⅳ Non-small Cell Lung.Cancer (NSCLC) who failed with first-line therapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors.
Rangamuwa K, Leong T, Weeden C, Asselin-Labat ML, et al · · 2021 · cited 65× · PMID 34295682 · DOI 10.21037/tlcr-20-1075
Contribution of immune cells in synergistic anti-tumor effect of ablation and immunotherapy.
He N, Jiang J. · · 2024 · cited 8× · PMID 38070356 · DOI 10.1016/j.tranon.2023.101859
Combining energy-based focal ablation and immune checkpoint inhibitors: preclinical research and clinical trials.
Jiang M, Fiering S, Shao Q. · · 2023 · cited 7× · PMID 37251920 · DOI 10.3389/fonc.2023.1153066
<i>In-situ</i> tumor vaccination by percutaneous ablative therapy and its synergy with immunotherapeutics: An update on combination therapy.
Kim NJ, Yoon JH, Tuomi AC, Lee J, et al · · 2023 · cited 6× · PMID 36969248 · DOI 10.3389/fimmu.2023.1118845
[Advances and Challenges of Local Thermal Ablation in Non-small Cell Lung Cancer].
Gou Q, Zhou Z, Zhao M, Chen X, et al · · 2020 · cited 5× · PMID 32093455 · DOI 10.3779/j.issn.1009-3419.2020.02.06
Interventional oncology update.
Newbury A, Ferguson C, Valero DA, Kutcher-Diaz R, et al · · 2022 · cited 3× · PMID 35761853 · DOI 10.1016/j.ejro.2022.100430
[Current Status and Progress of Thermal Ablation Combined with Immunotherapy for Lung Tumors].
Liu B. · · 2022 · cited 1× · PMID 35477191 · DOI 10.3779/j.issn.1009-3419.2022.102.09
Interventional oncology and immunotherapy: current status and future perspectives.
Ma J, Wei Z, Ye X. · · 2025 · PMID 40264767 · DOI 10.3389/fimmu.2025.1541105

Verify or expand the search:

Other trials of Pembrolizumab

Trials testing the same drug.

NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07275216 — Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT06724042 — Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors · Phase 1 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Other Second Affiliated Hospital of Guangzhou Medical University trials

Trials by the same sponsor.

NCT06966830 — Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus · not yet recruiting
NCT06936683 — Herpes Simplex Virus Type 1 Infection/Reactivation of Patients With Severe Pneumonia（the HSV-SP Study） · not yet recruiting
NCT07374328 — Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus · Phase 1, PHASE2 · recruiting
NCT06904183 — Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT · Phase 2 · recruiting
NCT06904196 — Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03769129 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital of Guangzhou Medical University
Last refreshed: 25 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03769129.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing